P. Comoglio
Molecular Biology · 2002–2016
A researcher in the Science corpus: 8 papers; trusts 3 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 48 citations into it; #7,500 of 17,773 by trust here, #9,600 by citations
- Cancer Research — 26 citations into it
- Cell Biology — 21 citations into it
- Cellular and Molecular Neuroscience — 7 citations into it; #1,502 of 2,998 by trust here, #1,858 by citations
Whom P. Comoglio trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts P. Comoglio overall
Papers from P. Comoglio's perspective
Ordered by how strongly the researchers P. Comoglio trusts endorse each paper. Same corpus, a different order for every researcher.
- Met, metastasis, motility and more (Nature reviews. Molecular cell biology)
- Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. (Proceedings of the National Academy of Sciences of the United States of America)
- Scatter-factor and semaphorin receptors: cell signalling for invasive growth (Nature Reviews. Cancer)
- Epithelial-mesenchymal transitions in development and disease. (Cell)
- The basics of epithelial-mesenchymal transition. (Journal of Clinical Investigation)
- ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors (Nature Reviews. Cancer)
- Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. (Developmental Cell)
- Proliferation, cell cycle and apoptosis in cancer (Nature)
- Mechanisms of angiogenesis and arteriogenesis (Nature Medicine)
- RHO GTPASES in neuronal morphogenesis (Nature Reviews Neuroscience)
Their papers
- Scatter-factor and semaphorin receptors: cell signalling for invasive growth (2002) — 786 citations
- Drug development of MET inhibitors: targeting oncogene addiction and expedience (2008) — 845 citations
- MET signalling: principles and functions in development, organ regeneration and cancer (2010) — 1,225 citations
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) — 867 citations
- Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer (2013) — 633 citations
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011) — 894 citations
- To move or not to move? (2004) — 168 citations
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. (2003) — 1,357 citations